Is DCTH or PYPD more profitable?

Delcath Systems has a net margin of 0.62% compared to PolyPid's net margin of 0.00%. Delcath Systems' return on equity of 0.51% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Delcath Systems 0.62% 0.51% 0.46% PolyPid N/A -241.96% -126.91%

Is PYPD or CLPT more profitable?

PolyPid has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. ClearPoint Neuro's return on equity of -140.96% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% ClearPoint Neuro -71.57% -140.96% -36.98%

Does the media favor PYPD or CLPT?

In the previous week, ClearPoint Neuro had 1 more articles in the media than PolyPid. MarketBeat recorded 5 mentions for ClearPoint Neuro and 4 mentions for PolyPid. ClearPoint Neuro's average media sentiment score of 0.54 beat PolyPid's score of 0.47 indicating that ClearPoint Neuro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CV or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% PolyPid N/A -241.96% -126.91%

Which has stronger valuation and earnings, PYPD or CARL?

Carlsmed has higher revenue and earnings than PolyPid. Carlsmed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.91 N/A Carlsmed $50.51M 5.47 -$29.63M -$2.51 N/A

Is PYPD or CARL more profitable?

PolyPid has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Carlsmed -57.76% -60.74% -29.84%

Does the media favor PYPD or CARL?

In the previous week, PolyPid had 2 more articles in the media than Carlsmed. MarketBeat recorded 4 mentions for PolyPid and 2 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.89 beat PolyPid's score of 0.47 indicating that Carlsmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Carlsmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is PYPD or ELMD more profitable?

Electromed has a net margin of 11.34% compared to PolyPid's net margin of 0.00%. Electromed's return on equity of 15.71% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Electromed 11.34% 15.71% 13.37%

PolyPid (PYPD) Competitors

$4.72 -0.15 (-3.08%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$4.76 +0.04 (+0.74%)

As of 06/3/2026 05:05 PM Eastern

Compare

PYPD vs. DCTH, CLPT, CV, CARL, and ELMD

Should you buy PolyPid stock or one of its competitors? MarketBeat compares PolyPid with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PolyPid include Delcath Systems (DCTH), ClearPoint Neuro (CLPT), CapsoVision (CV), Carlsmed (CARL), and Electromed (ELMD). These companies are all part of the "medical equipment" industry.

How does PolyPid compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Delcath Systems has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Delcath Systems has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.18	$2.70M	$0.01	1,033.00
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

Delcath Systems has a net margin of 0.62% compared to PolyPid's net margin of 0.00%. Delcath Systems' return on equity of 0.51% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
PolyPid	N/A	-241.96%	-126.91%

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 19.4% of Delcath Systems shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Delcath Systems currently has a consensus price target of $22.50, indicating a potential upside of 117.81%. PolyPid has a consensus price target of $12.25, indicating a potential upside of 159.53%. Given PolyPid's stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, PolyPid had 3 more articles in the media than Delcath Systems. MarketBeat recorded 4 mentions for PolyPid and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.89 beat PolyPid's score of 0.47 indicating that Delcath Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Delcath Systems	Very Positive
PolyPid	Neutral

Summary

Delcath Systems beats PolyPid on 9 of the 14 factors compared between the two stocks.

How does PolyPid compare to ClearPoint Neuro?

PolyPid (NASDAQ:PYPD) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

PolyPid has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. ClearPoint Neuro's return on equity of -140.96% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

PolyPid has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

In the previous week, ClearPoint Neuro had 1 more articles in the media than PolyPid. MarketBeat recorded 5 mentions for ClearPoint Neuro and 4 mentions for PolyPid. ClearPoint Neuro's average media sentiment score of 0.54 beat PolyPid's score of 0.47 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ClearPoint Neuro has higher revenue and earnings than PolyPid. ClearPoint Neuro is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
ClearPoint Neuro	$36.97M	10.79	-$25.54M	-$1.01	N/A

26.5% of PolyPid shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PolyPid currently has a consensus price target of $12.25, suggesting a potential upside of 159.53%. ClearPoint Neuro has a consensus price target of $18.00, suggesting a potential upside of 35.34%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

ClearPoint Neuro beats PolyPid on 8 of the 15 factors compared between the two stocks.

How does PolyPid compare to CapsoVision?

CapsoVision (NASDAQ:CV) and PolyPid (NASDAQ:PYPD) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

PolyPid has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
PolyPid	N/A	-241.96%	-126.91%

CapsoVision has higher revenue and earnings than PolyPid. CapsoVision is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	25.18	-$25.32M	-$2.34	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

CapsoVision currently has a consensus target price of $8.50, indicating a potential upside of 24.45%. PolyPid has a consensus target price of $12.25, indicating a potential upside of 159.53%. Given PolyPid's stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, PolyPid had 3 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for PolyPid and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat PolyPid's score of 0.47 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
PolyPid	Neutral

26.5% of PolyPid shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

PolyPid beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does PolyPid compare to Carlsmed?

PolyPid (NASDAQ:PYPD) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

PolyPid currently has a consensus price target of $12.25, suggesting a potential upside of 159.53%. Carlsmed has a consensus price target of $19.33, suggesting a potential upside of 90.08%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts clearly believe PolyPid is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, PolyPid had 2 more articles in the media than Carlsmed. MarketBeat recorded 4 mentions for PolyPid and 2 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.89 beat PolyPid's score of 0.47 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Carlsmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PolyPid has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Carlsmed	-57.76%	-60.74%	-29.84%

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Carlsmed has higher revenue and earnings than PolyPid. Carlsmed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Carlsmed	$50.51M	5.47	-$29.63M	-$2.51	N/A

Summary

PolyPid beats Carlsmed on 9 of the 14 factors compared between the two stocks.

How does PolyPid compare to Electromed?

PolyPid (NASDAQ:PYPD) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Electromed has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Electromed	$71.75M	4.11	$5.15M	$1.17	30.47

Electromed has a net margin of 11.34% compared to PolyPid's net margin of 0.00%. Electromed's return on equity of 15.71% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Electromed	11.34%	15.71%	13.37%

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PolyPid currently has a consensus target price of $12.25, indicating a potential upside of 159.53%. Electromed has a consensus target price of $37.50, indicating a potential upside of 5.19%. Given PolyPid's higher possible upside, analysts clearly believe PolyPid is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

In the previous week, PolyPid had 4 more articles in the media than Electromed. MarketBeat recorded 4 mentions for PolyPid and 0 mentions for Electromed. Electromed's average media sentiment score of 1.00 beat PolyPid's score of 0.47 indicating that Electromed is being referred to more favorably in the news media.

Company	Overall Sentiment
PolyPid	Neutral
Electromed	Positive

PolyPid has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Electromed has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Summary

Electromed beats PolyPid on 11 of the 16 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$92.93M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-2.47	17.69	22.39	24.18
Price / Sales	N/A	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	6.84	3.85	9.84	6.72
Net Income	-$34.17M	$75.85M	$3.57B	$337.19M
7 Day Performance	-1.05%	-1.67%	-1.16%	0.48%
1 Month Performance	6.31%	22.18%	3.85%	5.07%
1 Year Performance	50.32%	21.83%	27.40%	34.25%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYPD PolyPid	2.7521 of 5 stars	$4.72 -3.1%	$12.25 +159.5%	+50.3%	$92.93M	N/A	N/A	80
DCTH Delcath Systems	2.4967 of 5 stars	$10.83 -1.7%	$22.50 +107.8%	-35.8%	$380.43M	$85.23M	1,083.00	60	Positive News
CLPT ClearPoint Neuro	3.0839 of 5 stars	$11.82 +3.3%	$18.00 +52.3%	+5.1%	$343.08M	$36.97M	N/A	110	Gap Up
CV CapsoVision	1.8624 of 5 stars	$6.62 -0.3%	$8.50 +28.4%	N/A	$331.76M	$13.56M	N/A	90
CARL Carlsmed	4.1633 of 5 stars	$11.89 -1.8%	$19.33 +62.6%	N/A	$329.21M	$50.51M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors

PYPD vs. DCTH, CLPT, CV, CARL, and ELMD

How does PolyPid compare to Delcath Systems?

Summary

How does PolyPid compare to ClearPoint Neuro?

Summary

How does PolyPid compare to CapsoVision?

Summary

How does PolyPid compare to Carlsmed?

Summary

How does PolyPid compare to Electromed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PolyPid (PYPD) Competitors

PYPD vs. DCTH, CLPT, CV, CARL, and ELMD

How does PolyPid compare to Delcath Systems?

Which has more volatility and risk, DCTH or PYPD?

Which has stronger valuation and earnings, DCTH or PYPD?

Is DCTH or PYPD more profitable?

Do institutionals and insiders believe in DCTH or PYPD?

Do analysts rate DCTH or PYPD?

Does the media refer more to DCTH or PYPD?

Summary

How does PolyPid compare to ClearPoint Neuro?

Is PYPD or CLPT more profitable?

Which has more risk & volatility, PYPD or CLPT?

Does the media favor PYPD or CLPT?

Which has preferable valuation & earnings, PYPD or CLPT?

Do insiders and institutionals have more ownership in PYPD or CLPT?

Do analysts rate PYPD or CLPT?

Summary

How does PolyPid compare to CapsoVision?

Is CV or PYPD more profitable?

Which has higher valuation & earnings, CV or PYPD?

Do analysts rate CV or PYPD?

Does the media refer more to CV or PYPD?

Do insiders and institutionals believe in CV or PYPD?

Summary

How does PolyPid compare to Carlsmed?

Do analysts rate PYPD or CARL?

Does the media favor PYPD or CARL?

Is PYPD or CARL more profitable?

Do insiders & institutionals believe in PYPD or CARL?

Which has stronger valuation and earnings, PYPD or CARL?

Summary

How does PolyPid compare to Electromed?

Which has better valuation and earnings, PYPD or ELMD?

Is PYPD or ELMD more profitable?

Do insiders & institutionals believe in PYPD or ELMD?

Do analysts rate PYPD or ELMD?

Does the media prefer PYPD or ELMD?

Which has more risk and volatility, PYPD or ELMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools